Extended trial tests Drug's safety for debilitating liver disease itch

NCT ID NCT04167358

Ongoing Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study aims to evaluate the long-term safety and tolerability of linerixibat, a medication for severe itching caused by primary biliary cholangitis, a chronic liver disease. The trial includes 242 adults who previously participated in linerixibat studies and will continue receiving the drug. Researchers will monitor side effects and quality of life measures over time to understand how safe the treatment is for extended use.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Davis, California, 95817, United States
GSK Investigational Site

West Hollywood, California, 90048, United States
GSK Investigational Site

Miami, Florida, 33136, United States
GSK Investigational Site

Detroit, Michigan, 48377, United States
GSK Investigational Site

New York, New York, 10016, United States
GSK Investigational Site

Durham, North Carolina, 27710, United States
GSK Investigational Site

Morrisville, North Carolina, 27560, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Dallas, Texas, 75390, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

Seattle, Washington, 98105, United States
GSK Investigational Site

Buenos Aires, C1061AAS, Argentina
GSK Investigational Site

Capital Federal, C1181ACI, Argentina
GSK Investigational Site

Ciudad AutOnoma de Buenos Aire, 1118, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1056ABI, Argentina
GSK Investigational Site

Rosario, S2002KDT, Argentina
GSK Investigational Site

Santa Fe, 3000, Argentina
GSK Investigational Site

Porto Alegre, Rio Grande do Sul, 90035003, Brazil
GSK Investigational Site

Botucatu, 18618686, Brazil
GSK Investigational Site

Brasília, 70335-900, Brazil
GSK Investigational Site

Salvador, 40110-160, Brazil
GSK Investigational Site

Sofia, 1618, Bulgaria
GSK Investigational Site

Edmonton, Alberta, T6G 2X8, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2C4, Canada
GSK Investigational Site

Beijing, 100032, China
GSK Investigational Site

Beijing, 100069, China
GSK Investigational Site

Changchun, 130021, China
GSK Investigational Site

Chongqing, 400042, China
GSK Investigational Site

Guangzhou, 510630, China
GSK Investigational Site

Nanchang, 330006, China
GSK Investigational Site

Nanjing, 210003, China
GSK Investigational Site

Shanghai, 200127, China
GSK Investigational Site

Tianjin, 300000, China
GSK Investigational Site

Pilsen, 30100, Czechia
GSK Investigational Site

Prague, 140 21, Czechia
GSK Investigational Site

Lille, 59037, France
GSK Investigational Site

Erlangen, 91054, Germany
GSK Investigational Site

Münster, 48149, Germany
GSK Investigational Site

Haifa, 34362, Israel
GSK Investigational Site

Holon, 58100, Israel
GSK Investigational Site

Jerusalem, 91120, Israel
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Negrar Verona, 37024, Italy
GSK Investigational Site

Palermo, 90127, Italy
GSK Investigational Site

Roma, 00168, Italy
GSK Investigational Site

Chiba, 270-1694, Japan
GSK Investigational Site

Ehime, 791-0295, Japan
GSK Investigational Site

Fukui, 918-8503, Japan
GSK Investigational Site

Gunma, 371-8511, Japan
GSK Investigational Site

Hiroshima, 730-8619, Japan
GSK Investigational Site

Hiroshima, 734-8551, Japan
GSK Investigational Site

Hokkaido, 006-8555, Japan
GSK Investigational Site

Kagawa, 760-8557, Japan
GSK Investigational Site

Kanagawa, 259-1143, Japan
GSK Investigational Site

Nagano, 390-8621, Japan
GSK Investigational Site

Nagasaki, 856-8562, Japan
GSK Investigational Site

Nara, 634-8522, Japan
GSK Investigational Site

Osaka, 545-8586, Japan
GSK Investigational Site

Osaka, 591-8025, Japan
GSK Investigational Site

Shizuoka, 431-3192, Japan
GSK Investigational Site

Tokyo, 113-8603, Japan
GSK Investigational Site

Tokyo, 162-8655, Japan
GSK Investigational Site

Tokyo, 173-8606, Japan
GSK Investigational Site

Tokyo, 181-8611, Japan
GSK Investigational Site

Mexico City, 06700, Mexico
GSK Investigational Site

Mexico City, 14080, Mexico
GSK Investigational Site

Monterrey, 64020, Mexico
GSK Investigational Site

Częstochowa, 42-217, Poland
GSK Investigational Site

Katowice, 40-659, Poland
GSK Investigational Site

Mysłowice, 41-400, Poland
GSK Investigational Site

Warsaw, 03-712, Poland
GSK Investigational Site

Wroclaw, 51-162, Poland
GSK Investigational Site

Kemerovo, 650000, Russia
GSK Investigational Site

Moscow, 119121, Russia
GSK Investigational Site

Samara, 443063, Russia
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Valencia, 46026, Spain
GSK Investigational Site

Basingstoke, RG24 9NA, United Kingdom
GSK Investigational Site

Glasgow, G31 2ER, United Kingdom
GSK Investigational Site

London, NW3 2QG, United Kingdom
GSK Investigational Site

Newcastle upon Tyne, NE4 5PL, United Kingdom
GSK Investigational Site

Nottingham, NG7 2UH, United Kingdom
GSK Investigational Site

Plymouth, PL6 8DH, United Kingdom
GSK Investigational Site

Reading Berkshire, RG1 5AN, United Kingdom
GSK Investigational Site

Southampton, SO16 6YD, United Kingdom
GSK Investigational Site

Surrey, RH1 5RH, United Kingdom

Conditions

Explore the condition pages connected to this study.

CHOLESTASIS